Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib is a small-molecule tyrosine kinase inhibitor that selectively targets and inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), thereby blocking tumor angiogenesis. It was approved by the China Food and Drug Administration in 2014 for treating advanced gastric cancer patients who have failed second-line treatment. In the context of studies conducted by Henan Cancer Hospital, apatinib is being investigated in combination with various PD-1 inhibitors (such as camrelizumab, sintilimab, or tislelizumab) for patients with advanced gastric cancer or gastroesophageal junction cancer. This combination therapy aims to enhance anti-tumor immune responses by combining anti-angiogenic effects with immune checkpoint inhibition, potentially overcoming resistance in previously treated patients.
- Brand names
- AiTan
- Other names
- YN968D1YN-968D1YN 968D1Rivoceranib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + PD-1 inhibitor.